| Trial Identifier: | D3250C00025 |
| Sponsor: | AstraZeneca |
| Collaborator: |
IQVIA
Parexel
Covance
PPD
|
| Start Date: | November 2019 |
| Primary Completion Date: | September 2022 |
| Study Completion Date: | September 2022 |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| English Version | |
| Spanish (United States) Translation | |
| Japanese Translation |
| Country | Location |
|---|---|
| JP | Fukuoka-shi, JP, 813-0017 |
| JP | Fukuoka-shi, JP, 811-1394 |
| JP | Fukuyama-shi, JP, 721-8511 |
| JP | Gifu-shi, JP, 500-8717 |
| JP | Habikino-shi, JP, 583-8588 |
| JP | Saga-shi, JP, 840-8571 |
| JP | Tsu-shi, JP, 514-0125 |
| JP | Zentsuji-shi, JP, 765-8507 |
| US, CA | Los Angeles, CA, US, 90078 |
| US, FL | Orlando, FL, US, 32827 |
| US, NE | Lincoln, NE, US, 68505 |
| US, OH | Cincinnati, OH, US, 45229 |
| US, PA | Pittsburgh, PA, US, 15213 |
| US, TX | Coppell, TX, US, 75019 |
| US, TX | San Antonio, TX, US, 78251 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company